Targets › ITGB6
4 programs from 3 companies in 6 trials: 4 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.
Integrin alpha-V:beta-6 (ITGAV:ITGB6) is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. (UniProt, P18564)
Open in Phaseline: the race on ITGB6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | sigvotatug vedotin Integrin beta-6 binding agent | ITGB6 | Phase 3 | Carcinoma, Non-Small-Cell Lung; Carcinoma, Non-Small Cell Lung | Jun 2027 |
| Pfizer | Sigvotatug Vedotin Integrin beta-6 binding agent | ITGB6 | Phase 3 | Non-Small Cell Lung Cancer; Advanced/Metastatic Non-Small Cell Lung Cancer | Sep 2028 |
| University of California, Davis | [18F]-αvβ6-BP Fluorine-18-labeled αvβ6 integrin-binding peptide for PET imaging | ITGAV, ITGB6 | Phase 1 | Lung Cancer | Dec 2026 |
| Sutro Biopharma | STRO-006 ITGB6-targeting antibody-drug conjugate | ITGB6 | Phase 1 | Head & Neck Squamous Cell Carcinoma | Feb 2028 |
Carcinoma, Non-Small-Cell Lung (1) Carcinoma, Non-Small Cell Lung (1) Lung Cancer (1) Non-Small Cell Lung Cancer (1) Advanced/Metastatic Non-Small Cell Lung Cancer (1) Head & Neck Squamous Cell Carcinoma (1)
mixed (2), small molecule (1), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.